316 related articles for article (PubMed ID: 32661362)
1. Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity.
Liu C; Somasundaram A; Manne S; Gocher AM; Szymczak-Workman AL; Vignali KM; Scott EN; Normolle DP; John Wherry E; Lipson EJ; Ferris RL; Bruno TC; Workman CJ; Vignali DAA
Nat Immunol; 2020 Sep; 21(9):1010-1021. PubMed ID: 32661362
[TBL] [Abstract][Full Text] [Related]
2. Neuropilin-1 Regulates the Secondary CD8 T Cell Response to Virus Infection.
Hwang JY; Sun Y; Carroll CR; Usherwood EJ
mSphere; 2019 May; 4(3):. PubMed ID: 31118303
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
4. Neuropilin-1 expression is induced on tolerant self-reactive CD8+ T cells but is dispensable for the tolerant phenotype.
Jackson SR; Berrien-Elliott M; Yuan J; Hsueh EC; Teague RM
PLoS One; 2014; 9(10):e110707. PubMed ID: 25343644
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
6. Interferon-γ Drives T
Overacre-Delgoffe AE; Chikina M; Dadey RE; Yano H; Brunazzi EA; Shayan G; Horne W; Moskovitz JM; Kolls JK; Sander C; Shuai Y; Normolle DP; Kirkwood JM; Ferris RL; Delgoffe GM; Bruno TC; Workman CJ; Vignali DAA
Cell; 2017 Jun; 169(6):1130-1141.e11. PubMed ID: 28552348
[TBL] [Abstract][Full Text] [Related]
7. LRP11 promotes stem-like T cells via MAPK13-mediated TCF1 phosphorylation, enhancing anti-PD1 immunotherapy.
Sun L; Ma Z; Zhao X; Tan X; Tu Y; Wang J; Chen L; Chen Z; Chen G; Lan P
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272565
[TBL] [Abstract][Full Text] [Related]
8. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
Front Immunol; 2021; 12():637146. PubMed ID: 34025646
[TBL] [Abstract][Full Text] [Related]
9. Type 17 immunity promotes the exhaustion of CD8
Kim BS; Kuen DS; Koh CH; Kim HD; Chang SH; Kim S; Jeon YK; Park YJ; Choi G; Kim J; Kang KW; Kim HY; Kang SJ; Hwang S; Shin EC; Kang CY; Dong C; Chung Y
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083422
[TBL] [Abstract][Full Text] [Related]
10. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
[TBL] [Abstract][Full Text] [Related]
11. TOX promotes the exhaustion of antitumor CD8
Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
[TBL] [Abstract][Full Text] [Related]
12. Precursor exhausted T cells: key to successful immunotherapy?
Kallies A; Zehn D; Utzschneider DT
Nat Rev Immunol; 2020 Feb; 20(2):128-136. PubMed ID: 31591533
[TBL] [Abstract][Full Text] [Related]
13. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
[TBL] [Abstract][Full Text] [Related]
14. Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8
Enamorado M; Iborra S; Priego E; Cueto FJ; Quintana JA; Martínez-Cano S; Mejías-Pérez E; Esteban M; Melero I; Hidalgo A; Sancho D
Nat Commun; 2017 Jul; 8():16073. PubMed ID: 28714465
[TBL] [Abstract][Full Text] [Related]
15. MYB orchestrates T cell exhaustion and response to checkpoint inhibition.
Tsui C; Kretschmer L; Rapelius S; Gabriel SS; Chisanga D; Knöpper K; Utzschneider DT; Nüssing S; Liao Y; Mason T; Torres SV; Wilcox SA; Kanev K; Jarosch S; Leube J; Nutt SL; Zehn D; Parish IA; Kastenmüller W; Shi W; Buchholz VR; Kallies A
Nature; 2022 Sep; 609(7926):354-360. PubMed ID: 35978192
[TBL] [Abstract][Full Text] [Related]
16. Subsets of exhausted CD8
Miller BC; Sen DR; Al Abosy R; Bi K; Virkud YV; LaFleur MW; Yates KB; Lako A; Felt K; Naik GS; Manos M; Gjini E; Kuchroo JR; Ishizuka JJ; Collier JL; Griffin GK; Maleri S; Comstock DE; Weiss SA; Brown FD; Panda A; Zimmer MD; Manguso RT; Hodi FS; Rodig SJ; Sharpe AH; Haining WN
Nat Immunol; 2019 Mar; 20(3):326-336. PubMed ID: 30778252
[TBL] [Abstract][Full Text] [Related]
17. NKG2D induces Mcl-1 expression and mediates survival of CD8 memory T cell precursors via phosphatidylinositol 3-kinase.
Wensveen FM; Lenartic M; Jelencic V; Lemmermann NA; ten Brinke A; Jonjic S; Polic B
J Immunol; 2013 Aug; 191(3):1307-15. PubMed ID: 23804716
[TBL] [Abstract][Full Text] [Related]
18. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8
Hermans D; Gautam S; García-Cañaveras JC; Gromer D; Mitra S; Spolski R; Li P; Christensen S; Nguyen R; Lin JX; Oh J; Du N; Veenbergen S; Fioravanti J; Ebina-Shibuya R; Bleck C; Neckers LM; Rabinowitz JD; Gattinoni L; Leonard WJ
Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6047-6055. PubMed ID: 32123114
[TBL] [Abstract][Full Text] [Related]
19. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
20. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
